{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T01:45:14Z","timestamp":1791423914283,"version":"4.3.3"},"reference-count":27,"publisher":"American Academy of Pediatrics (AAP)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,4,1]]},"abstract":"<jats:p>BACKGROUND. The value of probiotics for primary prevention is controversial. Published trials vary considerably in study design and the applied probiotics, thereby limiting comparability of the results.<\/jats:p>\n                  <jats:p>OBJECTIVE. The purpose of this trial was to study the preventive effect of the probiotic Lactobacillus GG on the development of atopic dermatitis.<\/jats:p>\n                  <jats:p>METHODS. In a double-blind, placebo-controlled prospective trial, 105 pregnant women from families with \u22651 member (mother, father, or child) with an atopic disease were randomly assigned to receive either the probiotic Lactobacillus GG (American Type Culture Collection 53103; 5 \u00d7 109 colony-forming units of Lactobacillus GG twice daily) or placebo. Ninety-four families (89.5%) completed the trial. The supplementation period started 4 to 6 weeks before expected delivery, followed by a postnatal period of 6 months. The primary end point was the occurrence of atopic dermatitis at the age of 2 years. Secondary outcomes were severity of atopic dermatitis, recurrent episodes of wheezing bronchitis, and allergic sensitization at the age of 2 years.<\/jats:p>\n                  <jats:p>RESULTS. Atopic dermatitis was diagnosed in 14 (28%) of 50 in the Lactobacillus GG group and in 12 (27.3%) of 44 in the placebo group. The risk of atopic dermatitis in children on probiotics relative to placebo was 0.96 (confidence interval 0.38\u20132.33). Severity of atopic dermatitis was comparable between the 2 groups. Notably, children with recurrent (\u22655) episodes of wheezing bronchitis were more frequent in the Lactobacillus GG group (26%; n = 13), as compared with the placebo group (9.1%; n = 4). No difference was observed between both groups in total immunoglobulin E concentrations or numbers of specific sensitization to inhalant allergens.<\/jats:p>\n                  <jats:p>CONCLUSIONS. Supplementation with Lactobacillus GG during pregnancy and early infancy neither reduced the incidence of atopic dermatitis nor altered the severity of atopic dermatitis in affected children but was associated with an increased rate of recurrent episodes of wheezing bronchitis. Therefore, Lactobacillus GG cannot be generally recommended for primary prevention.<\/jats:p>","DOI":"10.1542\/peds.2007-1492","type":"journal-article","created":{"date-parts":[[2008,3,10]],"date-time":"2008-03-10T20:34:51Z","timestamp":1205181291000},"page":"e850-e856","source":"Crossref","is-referenced-by-count":305,"title":["Randomized, Double-Blind, Placebo-Controlled Trial of Probiotics for Primary Prevention: No Clinical Effects of\n                    <i>Lactobacillus<\/i>\n                    GG Supplementation"],"prefix":"10.1542","volume":"121","author":[{"given":"Matthias Volkmar","family":"Kopp","sequence":"first","affiliation":[{"name":"University Children's Hospital, Freiburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabell","family":"Hennemuth","sequence":"additional","affiliation":[{"name":"University Children's Hospital, Freiburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Heinzmann","sequence":"additional","affiliation":[{"name":"University Children's Hospital, Freiburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radvan","family":"Urbanek","sequence":"additional","affiliation":[{"name":"University Children's Hospital, Freiburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2008,4,1]]},"reference":[{"key":"2021120902093552000_R1","doi-asserted-by":"crossref","unstructured":"Russell G. The childhood asthma epidemic. Thorax.\u20082006;61(4):276\u2013278","DOI":"10.1136\/thx.2005.052662"},{"key":"2021120902093552000_R2","doi-asserted-by":"crossref","unstructured":"von Hertzen L, Haahtela T. Disconnection of man and the soil: reason for the asthma and atopy epidemic?J Allergy Clin Immunol.\u20082006;117(2):334\u2013344","DOI":"10.1016\/j.jaci.2005.11.013"},{"key":"2021120902093552000_R3","doi-asserted-by":"crossref","unstructured":"Strachan DP. Hay fever, hygiene, and household size. BMJ.\u20081989;299(6710):1259\u20131260","DOI":"10.1136\/bmj.299.6710.1259"},{"key":"2021120902093552000_R4","doi-asserted-by":"crossref","unstructured":"Strachan DP. Family size, infection and atopy: the first decade of the \u201chygiene hypothesis. \u201d Thorax.\u20082000;55(suppl 1):S2\u2013S10","DOI":"10.1136\/thorax.55.suppl_1.S2"},{"key":"2021120902093552000_R5","doi-asserted-by":"crossref","unstructured":"Prescott SL, Macaubas C, Holt BJ, et al. Transplacental priming of the human immune system to environmental allergens: universal skewing of initial T cell responses toward the Th2 cytokine profile. J Immunol.\u20081998;160(10):4730\u20134737","DOI":"10.4049\/jimmunol.160.10.4730"},{"key":"2021120902093552000_R6","doi-asserted-by":"crossref","unstructured":"Kopp MV, Zehle C, Pichler J, et al. Allergen-specific T cell reactivity in cord blood: the influence of maternal cytokine production. Clin Exp Allergy.\u20082001;31(10):1536\u20131543","DOI":"10.1046\/j.1365-2222.2001.01198.x"},{"key":"2021120902093552000_R7","doi-asserted-by":"crossref","unstructured":"Prescott SL, Macaubas C, Smallacombe T, Holt BJ, Sly PD, Holt PG. Development of allergen-specific T-cell memory in atopic and normal children. Lancet.\u20081999;353(9148):196\u2013200","DOI":"10.1016\/S0140-6736(98)05104-6"},{"key":"2021120902093552000_R8","doi-asserted-by":"crossref","unstructured":"Sudo N, Sawamura S, Tanaka K, Aiba Y, Kubo C, Koga Y. The requirement of intestinal bacterial flora for the development of an IgE production system fully susceptible to oral tolerance induction. J Immunol.\u20081997;159(4):1739\u20131745","DOI":"10.4049\/jimmunol.159.4.1739"},{"key":"2021120902093552000_R9","doi-asserted-by":"crossref","unstructured":"Riedler J, Braun-Fahrlander C, Eder W, et al. Exposure to farming in early life and development of asthma and allergy: a cross-sectional survey. Lancet.\u20082001;358(9288):1129\u20131133","DOI":"10.1016\/S0140-6736(01)06252-3"},{"key":"2021120902093552000_R10","doi-asserted-by":"crossref","unstructured":"Sepp E, Julge K, Mikelsaar M, Bjorksten B. Intestinal microbiota and immunoglobulin E responses in 5-year-old Estonian children. Clin Exp Allergy.\u20082005;35(9):1141\u20131146","DOI":"10.1111\/j.1365-2222.2005.02315.x"},{"key":"2021120902093552000_R11","doi-asserted-by":"crossref","unstructured":"Kallioma\u0308ki M, Kirjavainen P, Eerola E, Kero P, Salminen S, Isolauri E. Distinct patterns of neonatal gut microflora in infants developing or not developing atopy. J Allergy Clin Immunol.\u20082001;107(1):129\u2013134","DOI":"10.1067\/mai.2001.111237"},{"key":"2021120902093552000_R12","doi-asserted-by":"crossref","unstructured":"Bjo\u0308rkste\u0301n B, Sepp E, Julge K, Voor T, Mikelsaar M. Allergy development and the intestinal microflora during the first year of life. J Allergy Clin Immunol.\u20082001;108(4):516\u2013520","DOI":"10.1067\/mai.2001.118130"},{"key":"2021120902093552000_R13","doi-asserted-by":"crossref","unstructured":"Havenaar R, Huis in 't Veld JHJ. Probiotics: a general view. In: Wood, BJB, ed. Lactic Acid Bacteria in Health and Disease. Vol 1 of The Lactic Acid Bacteria. Amsterdam, Netherlands: Elsevier Applied Science Publishers; 1992","DOI":"10.1007\/978-1-4615-3522-5_6"},{"key":"2021120902093552000_R14","doi-asserted-by":"crossref","unstructured":"Kallioma\u0308ki M, Salminen S, Arvilommi H, Kero P, Koskinen P, Isolauri E. Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial. Lancet.\u20082001;357(9262):1076\u20131079","DOI":"10.1016\/S0140-6736(00)04259-8"},{"key":"2021120902093552000_R15","doi-asserted-by":"crossref","unstructured":"Kallioma\u0308ki M, Salminen S, Poussa T, Arvilommi H, Isolauri E. Probiotics and prevention of atopic disease: 4-year follow-up of a randomised placebo-controlled trial. Lancet.\u20082003;361(9372):1869\u20131871","DOI":"10.1016\/S0140-6736(03)13490-3"},{"key":"2021120902093552000_R16","doi-asserted-by":"crossref","unstructured":"Kallioma\u0308ki M, Salminen S, Poussa T, Isolauri E. Probiotics during the first 7 years of life: a cumulative risk reduction of eczema in a randomized, placebo-controlled trial. J Allergy Clin Immunol.\u20082007;119(4):1019\u20131021","DOI":"10.1016\/j.jaci.2006.12.608"},{"key":"2021120902093552000_R17","doi-asserted-by":"crossref","unstructured":"Taylor AL, Dunstan JA, Prescott SL. Probiotic supplementation for the first 6 months of life fails to reduce the risk of atopic dermatitis and increases the risk of allergen sensitization in high-risk children: a randomized controlled trial. J Allergy Clin Immunol.\u20082007;119(1):184\u2013191","DOI":"10.1016\/j.jaci.2006.08.036"},{"key":"2021120902093552000_R18","doi-asserted-by":"crossref","unstructured":"Williams HC, Burney PG, Pembroke AC, Hay RJ. The U.K. Working Party's Diagnostic Criteria for Atopic Dermatitis III: independent hospital validation. Br J Dermatol.\u20081994;131(3):406\u2013416","DOI":"10.1111\/j.1365-2133.1994.tb08532.x"},{"key":"2021120902093552000_R19","doi-asserted-by":"crossref","unstructured":"Severity scoring of atopic dermatitis\u2013the SCORAD index: Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology.\u20081993;186(1):23\u201331","DOI":"10.1159\/000247298"},{"key":"2021120902093552000_R20","doi-asserted-by":"crossref","unstructured":"Helin T, Haahtela S, Haahtela T. No effect of oral treatment with an intestinal bacterial strain, Lactobacillus rhamnosus (ATCC 53103), on birch-pollen allergy: a placebo-controlled double-blind study. Allergy.\u20082002;57(3):185\u2013187","DOI":"10.1034\/j.1398-9995.2002.1s3299.x"},{"key":"2021120902093552000_R21","doi-asserted-by":"crossref","unstructured":"Rosenfeldt V, Benfeldt E, Nielsen SD, et al. Effect of probiotic Lactobacillus strains in children with atopic dermatitis. J Allergy Clin Immunol.\u20082003;111(2):389\u2013395","DOI":"10.1067\/mai.2003.389"},{"key":"2021120902093552000_R22","doi-asserted-by":"crossref","unstructured":"Brouwer ML, Wolt-Plompen SA, Dubois AE, et al. No effects of probiotics on atopic dermatitis in infancy: a randomized placebo-controlled trial. Clin Exp Allergy.\u20082006;36(7):899\u2013906","DOI":"10.1111\/j.1365-2222.2006.02513.x"},{"key":"2021120902093552000_R23","doi-asserted-by":"crossref","unstructured":"Kukkonen K, Savilahti E, Haahtela T, et al. Probiotics and prebiotic galacto-oligosaccharides in the prevention of allergic diseases: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol.\u20082007;119(1):192\u2013198","DOI":"10.1016\/j.jaci.2006.09.009"},{"key":"2021120902093552000_R24","doi-asserted-by":"crossref","unstructured":"Abrahamsson TR, Jakobsson T, Bottcher MF, et al. Probiotics in prevention of IgE-associated eczema: a double-blind, randomized, placebo-controlled trial. J Allergy Clin Immunol.\u20082007;119(5):1174\u20131180","DOI":"10.1016\/j.jaci.2007.01.007"},{"key":"2021120902093552000_R25","doi-asserted-by":"crossref","unstructured":"Kaila M, Isolauri E, Soppi E, Virtanen E, Laine S, Arvilommi H. Enhancement of the circulating antibody secreting cell response in human diarrhea by a human Lactobacillus strain. Pediatr Res.\u20081992;32(2):141\u2013144","DOI":"10.1203\/00006450-199208000-00002"},{"key":"2021120902093552000_R26","doi-asserted-by":"crossref","unstructured":"Malin M, Verronen P, Korhonen H, et al. Dietary therapy with Lactobacillus GG, bovine colostrum or bovine immune colostrum in patients with juvenile chronic arthritis: evaluation of effect on gut defence mechanisms. Inflammopharmacology.\u20081997;5(3):219\u2013236","DOI":"10.1007\/s10787-997-0001-1"},{"key":"2021120902093552000_R27","doi-asserted-by":"crossref","unstructured":"Pessi T, Isolauri E, Su\u0308tas Y, Kankaanranta H, Moilanen E, Hurme M. Suppression of T cell activation by Lactobacillus rhamnosus GG-degraded bovine casein. Immunopharmacology.\u20082001;1(3):211\u2013218","DOI":"10.1016\/S1567-5769(00)00018-7"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/121\/4\/e850\/1123291\/zpe0040800e850.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/121\/4\/e850\/1123291\/zpe0040800e850.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T19:33:54Z","timestamp":1684265634000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/121\/4\/e850\/70793\/Randomized-Double-Blind-Placebo-Controlled-Trial"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,4,1]]},"references-count":27,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2008,4,1]]},"published-print":{"date-parts":[[2008,4,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2007-1492","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.1103972.561126","asserted-by":"object"}]},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,4,1]]}}}